TERT promoter mutations were also associated with adverse outcomes including tumor persistence/recurrence (OR, 4.97; 95% CI, 3.78–6.53; P < 0.05) and disease-specific mortality (OR, 8.29; 95% CI, 5.57–12.34; P < 0.05). The gene discussed is TERT; the disease is neoplasm.